Email Record: C014 | EFFICACY AND SAFETY OF IBRUTINIB AS SECOND-LINE TREATMENT IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS OF THE OLIMPUS STUDY